Recent developments in genome and exome-wide analyses of plasma lipids

Current Opinion in Lipidology

Volumn 26, Issue 2, 2015, Pages 96-102

  Lange, Leslie A ^a   Willer, Cristen J ^b   Rich, Stephen S ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

common variants; exome sequencing; genome wide association scan; rare variants

Indexed keywords

LIPID; ANTILIPEMIC AGENT;

CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EXOME SEQUENCING; FAMILIAL DISEASE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC EPIDEMIOLOGY; GENETIC TRAIT; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BLOOD; DNA SEQUENCE; DYSLIPIDEMIAS; EXOME; GENETIC PREDISPOSITION; GENETICS; LIPID METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; DYSLIPIDEMIAS; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS; MOLECULAR TARGETED THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84945558414     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000159     Document Type: Review

References (38)

1. Psaty BM, ODonnell CJ, Gudnason V, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE): design of prospective metaanalyses of genome-wide association studies. Circ Cardiovasc Genet 2009; 2:73-80.
2. Teslovich TM, Musununu K, Smith AV, et al. Biological, clinical, and population relevance of 95 loci mapped for serum lipid concentrations. Nature 2010; 466:707-713.
3. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants influence human height and cluster within genomic loci and biological pathways. Nature 2010; 467:832-838.
4. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249 796 individuals reveals 18 new loci associated with body mass index. Nat Genet 2010; 42:937-948.
5. ODonnell CJ, Kavousi M, Smith AV, et al. Genome-wide association study for coronary artery calcium with follow-up in myocardial infarction. Circulation 2011; 124:2855-2864.
6. Schunkert H, Konig IR, Kathiresan S, et al. Large-scale association analysis identified 13 new susceptiblity loci for coronary artery disease. Nat Genet 2011; 43:333-338.
7. Ng SB, Nickerson DA, Bamshad MJ, Shendure J. Massively parallel sequencing and rare disease. Hum Mol Genet 2010; 19:R119-R124.
8. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12:745-755.
9. Global Lipids Genetics Consortium. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45:1274-1283.
10. Polisecki E, Muallem H, Maeda N, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008; 200:109-114.
11. Donnelly LA, Doney AS, Dannfald J, et al. A paucimorphic variant in the HMGCoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008; 18:1021-1026.
12. Mangravite LM, Medina MW, Cui J, et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol 2010; 30:1485-1492.
13. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385:24-30.
14. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-Associated variation in regulatory DNA. Science 2012; 337:1190-1195.
15. Kellis M, Wold B, Snyder MP, et al. Defining functional DNA elements in the human genome. Proc Natl Acad Sci U S A 2014; 111:6131-6138.
16. Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010; 466:714-719.
17. Wang J, Williams CM, Hegele RA. Compound heterozygosity for two nonsynonymous polymorphisms in NPC1L1 in a nonresponder to ezetimibe. Clin Genet 2005; 67:175-177.
18. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156.
19. Cohen JC, Hobbs HH. Simple genetics for a complex disease. Science 2013; 340:689-690.
20. Trompet S, Jekema JW, Katan MB, et al. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 2009; 170:1415-1421.
21. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk for myocardial infarction: a Mendelian randomization study. Lancet 2012; 380:572-580.
22. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363:2220-2227.
23. Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33:2909-2914.
24. Futema M, Plagnol V, Li K, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 2014; 51:537-544.
25. Rosenthal EA, Ranchalis J, Crosslin DR, et al. Joint linkage and association analysis with exome sequence data implicates SLC25A40 in hypertriglyceridemia. Am J Hum Genet 2013; 93:1035-1045.
26. Lange LA, Hu Y, Zhang H, et al. Whole-Exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am J Hum Genet 2014; 94:233-245.
27. Noto D, Cefalu AB, Valenti V, et al. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler Thromb Vasc Biol 2012; 32:805-809.
28. Li B1, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008; 83:311-321.
29. Wu MC, Lee S, Cai T, et al. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 2011; 89:82-93.
30. TG and HDL Working Group of the Exome Sequencing Project. Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371:22-31.
31. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371:32-41.
32. Talmud PJ, Shah S, Whittall R, et al. Use of low-Density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381:1293-1301.
33. Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56 000 whites and blacks. Am J Hum Genet 2014; 94:223-232.
34. Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 2014; 46:345-351.
35. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk for coronary artery disease. Nat Genet 2008; 40:161-169.
36. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to noalcoholic fatty liver disease. Nat Genet 2014; 46:352-356.
37. Tachmazidou I, Dedoussis G, Southam L, et al. A rare functional cardioprotective APOC3 variant has risen in frequency in distinct population isolates. Nat Commun 2013; 4:2872.
38. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322:1702-1705.